t
| Date | 20 Jun 2024 |
| Time | 07:00:00 |
| Category | Miscellaneous |
| ID | nsm:202406200200PR_NEWS_UKDISCLO_0002.html |
Disseminated via PRN on 20 June 2024
PR Newswire
LONDON, United Kingdom, June 20
CAPITAL MARKETS DAY UPDATE 2
20 June 2024
Augmentum Fintech plc
Capital Markets Day Update 2
Augmentum Fintech plc (LSE: AUGM) (the "Company" or "Augmentum"), Europe's leading publicly listed fintech fund, is pleased to confirm further details of its upcoming Capital Markets Day. The in-person Capital Markets Day for institutional investors and analysts will take place on the morning of 27 June 2024 (8.15am - 1.30pm) in the City of London.
Confirmed speakers include representatives of the Portfolio Manager, and several Augmentum portfolio companies:
- Janine Hirt - CEO Innovate Finance
- David King - Founder & CEO, Artificial
- Christoph Rieche - Founder & CEO, Iwoca
- Oliver Prill - CEO, Tide
- Dan Garrett - Founder & CEO, Farewill
- Nigel Purves - Founder & CEO, Wayhome
- Jordan Lawrence - Founder & CGO, Volt
- Steve Hulme - CFO, Zopa
To register to attend the Capital Markets Day, and for further details, please contact: [email protected] . No material new information will be discussed at the event.
Enquiries
| Augmentum Fintech Tim Levene (Portfolio Manager) Martha Horrox (Marketing and IR) |
+44 (0)20 3961 5420 |
| Quill PR Nick Croysdill, Sarah Gibbons-Cook (Press and Media) |
+44 (0)20 7466 5050 |
| Peel Hunt LLP Liz Yong, Huw Jeremy (Investment Banking) |
+44 (0)20 7418 8900 |
| Singer Capital Markets Harry Gooden, Robert Peel, James Fischer (Investment Banking) |
+44 (0)20 7496 3000 |
| Frostrow Capital LLP Paul Griggs (Company Secretary) |
+44 (0)20 3709 8733 |
About Augmentum Fintech
Augmentum invests in fast growing fintech businesses that are disrupting the financial services sector. Augmentum is the UK's only publicly listed investment company focusing on the fintech sector in the UK and wider Europe, having launched on the main market of the London Stock Exchange in 2018, giving businesses access to patient capital and support, unrestricted by conventional fund timelines and giving public markets investors access to a largely privately held investment sector during its main period of growth.
